PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29777633-3 2018 We investigated whether inhaled beta2 -agonist, terbutaline, alters body composition and metabolic rate with and without concurrent exercise training in healthy young men. Terbutaline 48-59 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 32-37 31666899-1 2019 This study aimed to investigate the effects of beta2-agonist terbutaline sulfate (TER) at a supra-therapeutic dose (8 mg) on aerobic exercise performance. Terbutaline 61-80 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 47-52 31666899-1 2019 This study aimed to investigate the effects of beta2-agonist terbutaline sulfate (TER) at a supra-therapeutic dose (8 mg) on aerobic exercise performance. Terbutaline 82-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 47-52 30285125-3 2019 Design: The study was a randomized, placebo-controlled crossover trial where 10 healthy men received either infusion of beta2-agonist terbutaline (0.2 to 0.4 mg) or placebo. Terbutaline 134-145 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 120-125 27461883-0 2017 Terbutaline: level the playing field for inhaled beta2-agonists by introducing a dosing and urine threshold. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 49-54 27461883-1 2017 Terbutaline, a short-acting beta2-agonist similar to salbutamol, is widely used in Europe in the treatment of asthma and exercise-induced bronchoconstriction. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 28-33 27461883-4 2017 It is likely that the ergogenic effects of terbutaline are class specific for all beta2-agonists. Terbutaline 43-54 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-87 23899894-3 2014 This study explored central and peripheral neuromuscular adjustments of the quadriceps induced by beta2-agonist terbutaline after fatiguing exercise. Terbutaline 112-123 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 98-103 27480802-1 2016 This study investigated the effect of the beta2 receptor agonist terbutaline on the single channel activity of BKCa channel. Terbutaline 65-76 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 42-47 26197029-1 2016 PURPOSE: The aim of the present study was to investigate the effects of the beta2-agonist terbutaline (TER) on power output and muscle metabolism during maximal sprint cycling. Terbutaline 90-101 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 76-81 26634602-2 2015 beta;2-agonists can be broadly classified according to their duration of action: short-acting beta2-agonists (SABAs), including albuterol, terbutaline and fenoterol, have pharmacodynamics halflives between 2 and 6 h and long-acting beta2-agonists (LABAs), including salmeterol and formoterol, require twice daily treatment. Terbutaline 139-150 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-6 26634602-2 2015 beta;2-agonists can be broadly classified according to their duration of action: short-acting beta2-agonists (SABAs), including albuterol, terbutaline and fenoterol, have pharmacodynamics halflives between 2 and 6 h and long-acting beta2-agonists (LABAs), including salmeterol and formoterol, require twice daily treatment. Terbutaline 139-150 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 94-99 28137226-10 2017 Subcutaneous and intramuscular beta2 agonists such as terbutaline and epinephrine may be considered for children with severe asthma exacerbation who have poor air entry, are uncooperative with nebulized therapy, or have poor response to nebulized therapy. Terbutaline 54-65 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 31-36 23548654-7 2013 Terbutaline is a beta-2 agonist available in oral dosage form. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 17-23 24341818-4 2014 This review found that administration of beta2-agonist bronchodilators via dry powder inhalers (formoterol, salbutamol, terbutaline and budesonide/formoterol) was effective during severe asthma worsening and acute asthma attacks, and was as effective as established therapies with a pressurized metered-dose inhaler with or without a spacer, or nebulization. Terbutaline 120-131 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 41-46 23299764-3 2013 This study investigated central and peripheral neuromuscular adjustments induced by beta(2)-agonist terbutaline on a predominantly slow human muscle, the soleus. Terbutaline 100-111 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 84-90 23348973-4 2013 Traditional inhaled short-acting beta2-agonists albuterol, fenoterol, and terbutaline provide rapid as-needed symptom relief and short-term prophylactic protection against bronchoconstriction induced by exercise or other stimuli. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 33-38 24030662-2 2013 In animals, the short-acting beta2-agonist terbutaline has been shown to reduce dry airflow-induced bronchoconstriction and the associated shedding of airway epithelial cells. Terbutaline 43-54 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 29-34 23539880-1 2013 Beta2-adrenergic agonist medications such as albuterol and terbutaline are often prescribed during pregnancy to treat conditions such as asthma, pulmonary disease, preterm labor, or acute non-reassuring fetal heart rate abnormalities during labor. Terbutaline 59-70 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-5 22813780-1 2013 Terbutaline, a beta2-adrenoceptor agonist, is used off-label for long-term management of preterm labor; such use is associated with increased risk of neurodevelopmental disorders, including autism spectrum disorders. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 15-20 22813780-7 2013 Thus, terbutaline, operating through trophic interactions with beta2-adrenoceptors, impairs development of noradrenergic projections in a manner similar to that previously reported for its effects on the same neurotransmitter systems in the immature cerebellum. Terbutaline 6-17 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 63-68 22842339-1 2012 BACKGROUND: Short-acting beta2-agonists like salbutamol and terbutaline are used as rescue medications for acute bronchoconstriction and relief of symptoms due to their rapid onset of action. Terbutaline 60-71 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 25-30 22742717-6 2012 Increases in HR, CO, and SV with terbutaline were greater for those homozygous for the beta2 Glu27 allele than those with >=1 Gln27 allele (change in HR 13.7 vs 4.8 beats/min, p = 0.048; change in CO 3.1 vs 1.6 L/min, p = 0.034; change in SV 28.3 vs 14.8 ml, p = 0.045). Terbutaline 33-44 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 87-92 15655528-6 2005 Those beta2-adrenoceptor agonists used clinically for the treatment of asthma and COPD were beta2 selective: 29-, 61- and 2818-fold for salbutamol, terbutaline and salmeterol over beta1, respectively. Terbutaline 148-159 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 6-11 20355173-1 2009 Terbutaline is a fast-acting beta(2)-adrenergic agonist used in the treatment of obstructive pulmonary diseases. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 29-35 17986640-12 2008 The beta2-agonist, terbutaline, caused a marked concentration-dependent increase of muscle lactate and blood flow (P < 0.0001). Terbutaline 19-30 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-9 17211154-4 2007 The animal study showed that the suppression of glomerular function by terbutaline was associated with a reduction in systemic blood pressure and over-expression of renal beta2-ARs. Terbutaline 71-82 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 171-176 17211154-5 2007 Moreover, in rats over-expressing renal beta2-ARs, administration of terbutaline resulted in a high mortality rate after a lipopolysaccharide challenge. Terbutaline 69-80 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 40-45 16648137-4 2006 Broxaterol and terbutaline are agonists at beta(2)- and beta(3)-receptors; however, they act as antagonists at the beta(1)-subtype. Terbutaline 15-26 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 43-51 12205813-4 2002 Short-acting beta 2-agonists (salbutamol or albuterol, terbutaline) are indicated for asthma attacks, as needed in chronic asthma, and for prevention of symptoms during effort. Terbutaline 55-66 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-19 15373934-5 2004 RESULTS: Formoterol and terbutaline had significant beta2-adrenergic effects on most outcomes. Terbutaline 24-35 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 52-57 14982976-9 2004 Terbutaline is a beta2-adrenergic agonist that may mediate its effects via direct beta2-receptor stimulation, baroreceptor-mediated increases in sympathetic tone, or via presynaptic beta2-stimulation. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 17-22 14982976-9 2004 Terbutaline is a beta2-adrenergic agonist that may mediate its effects via direct beta2-receptor stimulation, baroreceptor-mediated increases in sympathetic tone, or via presynaptic beta2-stimulation. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-87 14982976-9 2004 Terbutaline is a beta2-adrenergic agonist that may mediate its effects via direct beta2-receptor stimulation, baroreceptor-mediated increases in sympathetic tone, or via presynaptic beta2-stimulation. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-87 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Terbutaline 213-224 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 186-192 15715182-4 2005 Traditional beta2-adrenoceptor agonists (beta2-agonists), such as salbutamol, terbutaline and fenoterol, were characterised by a rapid onset but relatively short duration of action. Terbutaline 78-89 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 12-17 15201362-5 2004 Infusion of the beta(2) agonist terbutaline was used to decrease plasma (and interstitial) K(+). Terbutaline 32-43 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 16-22 12510953-2 2002 Traditional inhaled short-acting beta2-agonists (salbutamol and terbutaline) provide rapid as-needed symptom relief and short-term prophylactic protection against bronchoconstriction induced by exercise or other stimuli. Terbutaline 64-75 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 33-38 14720033-1 2002 Beta2-adrenoceptor agonists (beta2-agonists) such as albuterol (salbutamol) and terbutaline and their long-acting analogs salmeterol and formoterol are widely used as bronchodilators in the treatment of asthma. Terbutaline 80-91 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 29-34 11818773-7 2002 RESULTS: Alveolar or intravenous lidocaine decreased alveolar fluid clearance by 50%, an effect that was reversible with the beta2 agonist, terbutaline. Terbutaline 140-151 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 125-130 11232861-2 2001 After hydrolysis of the conjugates with beta-glucuronidase/arylsulfatase a derivatisation step with formaldehyde converts fenoterol, orciprenaline, reproterol and terbutaline to one derivative, a tetrahydroisoquinoline, while the other beta-2 agonists remain unchanged. Terbutaline 163-174 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 236-242 16263481-5 2001 Beta2-agonists have been characterised into those which directly activate the receptor (salbutamol/terbutaline), those which are taken up into a membrane depot (formoterol) and those which interact with a receptor-specific, auxiliary binding site (salmeterol). Terbutaline 99-110 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-5 11509329-9 2001 The beta(2)-agonists salbutamol and terbutaline (100 microg/ml for 48 h) decreased ASF antibacterial activity by 5- to 8-fold. Terbutaline 36-47 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 11219455-3 2001 Terbutaline had only a slight lipolytic effect at 10(-5) M. This low effect could be due to a lower affinity of TER than of ISO for the beta2-adrenoceptors. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 136-141 9277405-4 1997 Gastrin release stimulated by terbutaline (beta 2-agonist) and forskolin was abolished by blockade of L-type VDCCs; the effect of 3.6 mM extracellular Ca2+ was only partially reversed. Terbutaline 30-41 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 43-49 11118019-2 2000 We used microdialysis to study the in situ lipolytic effects of dobutamine (selective beta1-agonist) and terbutaline (selective beta2-agonist) on glycerol release (lipolytic index) in abdominal subcutaneous AT in 10 obese girls aged 13-17 years, BMI 38 +/- 2.1 kg/m2, and in 7 lean girls aged 11-17 years, BMI 21 +/- 1.1 kg/m2, and compared them with 10 obese women aged 21-39 years, BMI 36 +/- 1.6 kg/m2, and 10 lean women aged 18-42 years, BMI 21 +/- 0.4 kg/m2. Terbutaline 105-116 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 128-133 10690878-5 2000 The beta2-adrenergic receptor agonist terbutaline inhibits tumor necrosis factor-alpha production and enhances interleukin-10 production by monocytes. Terbutaline 38-49 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-9 9647274-1 1998 BACKGROUND: Various studies have demonstrated the benefits of continuous nebulization therapy for delivering aerosols of the beta2 agonists such as terbutaline sulfate or albuterol sulfate to patients with severe asthma and/or impending respiratory failure. Terbutaline 148-167 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 125-130 9432097-13 1997 We conclude that inhalation of a beta2-agonist (terbutaline) in a dose that yields significant bronchodilatation does not influence physical performance at low temperature in healthy athletes. Terbutaline 48-59 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 33-38 14685585-0 1998 [Intravenous terbutaline in children] OBJECTIVE: The authors describe their experience with theuse of intravenous Beta2 adrenergic (IV terbutaline) in patientsadmitted to a PICU with severe lower airway obstruction. Terbutaline 13-24 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 114-119 14685585-0 1998 [Intravenous terbutaline in children] OBJECTIVE: The authors describe their experience with theuse of intravenous Beta2 adrenergic (IV terbutaline) in patientsadmitted to a PICU with severe lower airway obstruction. Terbutaline 135-146 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 114-119 9609581-1 1998 OBJECTIVE: Terbutaline, a selective beta2-agonist, is a frequently used tocolytic known to affect maternal metabolism. Terbutaline 11-22 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 36-41 9250445-1 1997 OBJECTIVE: To test the hypothesis that because of sustained glycemic actions, bedtime administration of the glucagon-releasing amino acid alanine or the epinephrine-simulating beta2-adrenergic agonist terbutaline more effectively prevents nocturnal hypoglycemia than a conventional bedtime snack, we studied 15 patients with IDDM. Terbutaline 201-212 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 176-181 8921745-4 1996 Only the enantiomers of the resorcinol type beta 2-agonists terbutaline and orciprenaline were separated in the CZE and HPLC systems, suggesting the position of substituents in the aromatic ring of beta 2-agonists has a profound effect on the enantioselectivity of complexation of these drugs with beta-CD. Terbutaline 60-71 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 44-50 9279294-1 1997 OBJECTIVE: The objective of this study was to investigate the effects of bambuterol (a prodrug of the beta 2-agonist terbutaline) on lipid and lipoprotein levels in patients with hyperlipidaemia. Terbutaline 117-128 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 102-108 9282409-3 1997 The first beta 2-stimulants to be introduced were shorter-acting drugs such as salbutamol and terbutaline. Terbutaline 94-105 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 10-16 9265155-0 1997 [Effect of the beta-2 mimetic drug terbutaline of growth hormone secretion in prepubertal asthmatic children]. Terbutaline 35-46 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 15-21 9265155-4 1997 The purpose of our study was to find out whether the beta-2 mimetic terbutalin, often used in asthma therapy, exercises a negative influence on the spontaneous release of growth hormone in children suffering from asthma. Terbutaline 68-78 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 53-59 8896942-1 1996 Bambuterol, a biscarbamate ester prodrug of the beta 2 adrenergic agonist terbutaline, has been approved for the treatment of asthma in 28 countries. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 8921745-4 1996 Only the enantiomers of the resorcinol type beta 2-agonists terbutaline and orciprenaline were separated in the CZE and HPLC systems, suggesting the position of substituents in the aromatic ring of beta 2-agonists has a profound effect on the enantioselectivity of complexation of these drugs with beta-CD. Terbutaline 60-71 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 198-204 7564908-5 1995 The beta 2-agonist terbutaline and salbutamol (4.10(-9) M when injected intraseptally also caused a decrease in urine flow and in renal Na+ and K+ excretion. Terbutaline 19-30 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 8902860-9 1996 Considering the general trend to noninvasive therapy in children and the more frequent adverse effects after epinephrine injection, such nebulized beta-2 agonists as terbutaline appear preferable for initial therapy of acute asthma if oxygen is supplemented to prevent possible hypoxemia. Terbutaline 166-177 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 147-153 8521164-9 1995 The pA2 for the selective beta 1- and beta 2-adrenoceptor antagonists versus CGP 12177-induced lipolysis were 2 to 3 log units lower than those for the beta 1-antagonist versus dobutamine or for the beta 2-antagonist versus terbutaline. Terbutaline 224-235 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 38-44 8200997-3 1994 First, an 80-fold decrease in sensitivity to the beta 2-selective agonist terbutaline (P < 0.001) which could be ascribed to a 50% reduced number of beta 2-receptors (P < 0.005) as determined with radioligand binding. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 49-55 8024220-6 1994 Challenge with the beta 2-agonist terbutaline sulfate produced an increase of mucociliary activity of 40.6% +/- 7.8% (mean +/- SEM), which is consistent with previous results in animal models. Terbutaline 34-53 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 19-25 8058076-1 1994 BACKGROUND: In a previous study, we found that two years of treatment with an inhaled corticosteroid, budesonide, was more effective than treatment with an inhaled beta 2-agonist, terbutaline, in patients with newly diagnosed, generally mild asthma. Terbutaline 180-191 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 164-170 8200997-3 1994 First, an 80-fold decrease in sensitivity to the beta 2-selective agonist terbutaline (P < 0.001) which could be ascribed to a 50% reduced number of beta 2-receptors (P < 0.005) as determined with radioligand binding. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 152-158 8095449-3 1993 Thus, we questioned whether the beta 2-adrenergic agonist, terbutaline, would improve mucociliary clearance in patients with CF as it does in healthy subjects. Terbutaline 59-70 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 32-38 8266020-2 1993 The beta-2 agonist terbutaline was given orally, 5 mg three times daily, for 10 days, and the subjects were studied before medication (basal), on days 3 and 10 during the medication, and 1 week after withdrawal of the drug. Terbutaline 19-30 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 7508184-3 1994 Because terbutaline, a beta 2-agonist, increases Na+ transport by FDLE, we studied its effect and selected signal transduction mechanisms on NSC channel activity. Terbutaline 8-19 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 23-29 8375242-1 1993 OBJECTIVE: To test the hypothesis that the amino acid Ala and the beta 2-adrenergic agonist terbutaline raise plasma glucose concentrations substantially, and do so through different mechanisms, in IDDM patients. Terbutaline 92-103 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 66-72 8375243-1 1993 OBJECTIVE: To test the hypothesis that, in contrast to administration of glucose or glucagon, administration of the amino acid Ala or of the beta 2-adrenergic agonist terbutaline produces sustained glucose recovery from hypoglycemia. Terbutaline 167-178 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 141-147 1358833-0 1992 Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Terbutaline 71-82 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 55-61 8122021-3 1993 The aim of this study is to assess the use of a beta-2-mimetic powder inhaler (Bricanyl Turbuhaler) in children presenting with an exacerbation of asthma. Terbutaline 79-98 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 1357551-8 1992 CONCLUSIONS: We observed tolerance to the nonbronchodilator actions of the inhaled beta 2-agonist terbutaline in patients with mild asthma, an effect that may be more pronounced in mast cells than in bronchial smooth muscle. Terbutaline 98-109 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 83-89 1429916-1 1992 We compared the changes in peak expiratory flow rate (PEFR), plasma potassium and plasma glucose during and after an infusion of the beta 2-agonist, terbutaline, in seven asthmatic subjects. Terbutaline 149-160 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 133-139 1320047-2 1992 The lipolytic sensitivity of the nonselective beta-agonists epinephrine and isoprenaline as well as the selective agonists norepinephrine (beta 1) and terbutaline (beta 2) was significantly increased 5-10 times in omental fat cells. Terbutaline 151-162 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 164-170 1629507-0 1992 A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. Terbutaline 99-110 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 83-89 1668078-0 1991 The adrenergic control of lipolysis: development of tolerance to beta-2 receptor stimulation with terbutaline. Terbutaline 98-109 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 65-71 1348869-1 1992 Short acting beta 2-agonists, such as salbutamol, fenoterol and terbutaline, are the most potent bronchodilating agents in the treatment of acute asthmatic attacks. Terbutaline 64-75 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-19 1973910-0 1990 Beta 2-adrenoceptors in human lung and peripheral mononuclear leukocytes of untreated and terbutaline-treated patients. Terbutaline 90-101 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-6 1681086-5 1991 On the other hand, isoprenaline plus a selective beta-1 receptor antagonist or the beta-2 selective adrenergic agonist terbutaline caused a constant lipolytic effect for at least 3 hr. Terbutaline 119-130 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 83-89 1718682-15 1991 The long-acting beta 2-agonists, including formoterol, represent a significant advance over current maintenance or prophylactic bronchodilator therapy with intermediate-acting beta 2-agonists such as salbutamol, fenoterol and terbutaline, predominantly because of the twice daily administration regimen. Terbutaline 226-237 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 16-22 2080624-5 1990 In 178 cases (98.3%) the infusion of a beta-2 adrenergic drug (hexoprenaline or terbutaline) led, without adverse effects, to the rapid resolution of the alarming findings. Terbutaline 80-91 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 39-45 1976296-7 1990 A beta 2-adrenergic drug (hexoprenaline or terbutaline) was infused routinely without adverse effects and with rapid resolution of the worrisome findings in 178 (98.3%) cases. Terbutaline 43-54 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 2-8 2692022-5 1989 However, those receiving terbutaline more frequently required the additional application of inhalative beta-2-sympathomimetics for respiratory distress. Terbutaline 25-36 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 103-109 2370646-2 1990 We have previously demonstrated, by giving an infusion of terbutaline to human volunteers, that beta 2-stimulation causes a rise in plasma glucose and a fall in plasma potassium. Terbutaline 58-69 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 96-102 2573312-1 1989 Administration of the beta 2 adrenergic agonists fenoterol, salbutamol and terbutaline to volunteers significantly reduced plasma potassium concentration in a double-blind crossover study. Terbutaline 75-86 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 22-28 2551559-5 1989 Healthy volunteers were treated for 7 days with the beta 2-selective agonist terbutaline (5 mg t.i.d.). Terbutaline 77-88 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 52-58 2724442-1 1989 The recent finding of terbutaline as the treatment of choice to manage intraoperative penile tumescence with the patient under anesthesia (general and regional) has prompted us to use this beta-2 agonist (5 mg. orally) for persistent penile erection and priapism resulting from injection of pharmacological agents, such as phentolamine, phenoxybenzamine and papavarine, into the penis for erectile impotence. Terbutaline 22-33 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 189-195 2565392-2 1989 Using pharmacokinetic-dynamic modeling in nonsteady-state conditions, of the antagonism by the beta blockers of the terbutaline-induced hypokalemia, the beta blocker beta-2 selectivity was quantitated in the terms of IC50 values representing plasma concentrations resulting in half-receptor occupancy. Terbutaline 116-127 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 166-172 3415546-1 1988 A randomized, double-masked study of the effect of terbutaline sulfate, a selective beta 2-agonist, on the rate of aqueous humor formation was performed in awake and sleeping normal human subjects. Terbutaline 51-70 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 84-90 2747008-1 1989 Plasma potassium lowering effect of a selective beta-2 adrenergic stimulant, terbutaline sulfate (TRB) was investigated in fourteen patients with chronic renal failure (CRF) receiving maintenance hemodialysis. Terbutaline 77-96 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 2747008-1 1989 Plasma potassium lowering effect of a selective beta-2 adrenergic stimulant, terbutaline sulfate (TRB) was investigated in fourteen patients with chronic renal failure (CRF) receiving maintenance hemodialysis. Terbutaline 98-101 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 2747008-6 1989 Thus, a beta-2 selective adrenergic stimulant, terbutaline sulfate may be useful for acute treatment of hyperkalemia in CRF patients by way of the stimulation of potassium uptake in the cells. Terbutaline 47-66 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 8-14 2562936-9 1989 The results with atenolol pretreatment indicate that cardiac beta 1 responses are associated with the higher dose of terbutaline, either through direct beta 1 stimulation or indirectly from presynaptic beta 2 activity. Terbutaline 117-128 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 202-208 2843407-6 1988 (-)-Norepinephrine, the unspecific beta-adrenergic agonist (-)-isoproterenol, and the beta 2-specific agonist terbutaline mimicked the effect of epinephrine on LDL-receptor activity. Terbutaline 110-121 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 86-92 2893778-0 1987 Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol. Terbutaline 103-114 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 87-93 3315268-8 1987 However, additional use of inhaled beta-2-mimetics because of asthmatic attacks occurred more often during terbutaline (79 times in 8/10 patients) than theophylline treatment (29 times in 5/10 patients). Terbutaline 107-118 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 35-41 3453755-1 1987 The effect of inhaling 0.25 and 2.0 mg of terbutaline sulphate, a beta-2-stimulant, from a metered dose aerosol was studied in five asthmatic patients during two periods of five days each. Terbutaline 42-62 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 66-72 3119689-9 1987 Single-dose pretreatment with the beta 2-agonist, terbutaline, inhibited generation of heat-labile NCA (p less than 0.001) but was without effect on LAR. Terbutaline 50-61 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 34-40 3026718-4 1987 In vivo, the beta 2-mediated plasma cyclic AMP response to isoprenaline was markedly attenuated during terbutaline treatment and was still reduced by 38% (P less than 0.05) 72 h after discontinuation of treatment. Terbutaline 103-114 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-19 2864159-12 1985 Aerosol administration is the route of choice for beta 2-adrenergic agonists for prophylaxis of exercise-induced bronchospasm; albuterol and terbutaline provide a prolonged duration of action with excellent beta 2-adrenergic selectivity. Terbutaline 141-152 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 207-213 2878632-2 1986 A single dose of the beta 2-agonist terbutaline (5 mg) and the beta 1 + 2-agonist orciprenaline (10 mg) did not reduce the fall in systolic pressure on standing up, despite a significant increase in both supine and standing heart rates. Terbutaline 36-47 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 21-27 3013487-8 1986 Alternative mechanisms for the cardiac changes with terbutaline include (1) withdrawal of vagal tone, (2) decrease in afterload, and (3) stimulation of cardiac beta 2-receptors. Terbutaline 52-63 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 160-166 2872714-9 1986 In comparison, norepinephrine stimulated AC activity to the same level as isoproterenol (three to four times basal activity) and the beta 2-selective agonist terbutaline caused some 50% of maximal AC stimulation. Terbutaline 158-169 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 133-139 2421600-1 1986 The site of antagonistic action on allergen-induced early skin reactions by the beta 2-agonist terbutaline was studied by light microscopy in 10 atopic subjects. Terbutaline 95-106 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 80-86 2995446-4 1985 After withdrawal of terbutaline beta 2-adrenoceptor, density and responsiveness gradually increased, reaching predrug levels after 4 d. Prednisone (1 X 100 mg orally) accelerated beta 2-adrenoceptor recovery; only 8-10 h after administration of the steroid beta 2-adrenoceptor density and cAMP responses to (-)-isoprenaline had reached values not significantly different from pretreatment levels. Terbutaline 20-31 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 32-38 2864131-2 1985 Both the beta1 agonist dobutamine and the beta2 agonist terbutaline relaxed coronary arteries partially contracted by 25 mM of KCl. Terbutaline 56-67 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 42-47 2869853-8 1986 Acute or intermittent asthma should be treated first with inhaled beta 2 agonists such as albuterol or terbutaline. Terbutaline 103-114 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 66-72 2995446-0 1985 Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 56-62 2863289-3 1985 Thereafter, terbutaline (0.5 mg), a beta2 agonist, was administered in aerosol form at 15-minute intervals for a total of five doses. Terbutaline 12-23 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 36-41 3861138-12 1985 The hyperactivity was readily countered with the beta 2-agonist, terbutaline. Terbutaline 65-76 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 49-55 2864739-8 1985 After infusion of the beta-1 agonist prenalterol and the beta-2 selective agonist terbutaline, a profound decrease in esophageal peristaltic amplitude was seen. Terbutaline 82-93 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 57-63 6434183-1 1984 Terbutaline sulfate, a relatively selective beta2 agonist, is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease. Terbutaline 0-19 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 44-49 6144326-5 1984 The beta 2-agonists terbutaline and salbutamol inhibited sterol synthesis by 42 and 26%, respectively, at a concentration of 0.1 mmol/l. Terbutaline 20-31 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 6150925-4 1984 The beta 2-selective agonist terbutaline, eg, causes bronchodilation with less beta 1-cardiac excitation than does the beta 1-beta 2 nonselective agonist isoproterenol. Terbutaline 29-40 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 6138106-4 1983 Subsequent treatment for 2 days with Prl, terbutaline (a beta 2-adrenergic agonist) or hCG stimulated the production of progesterone, 20 alpha-hydroxypregn-4-en-3-one (20 alpha-OH-P), pregnenolone and the activity of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD). Terbutaline 42-53 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 57-63 6188770-1 1983 Terbutaline, a preferential beta 2-adrenergic agonist, has been shown to inhibit allergen-induced histamine release in vitro. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 28-34 6136361-13 1983 To date, a betamimetic with selective beta 2 effects, such as terbutaline or ritodrine, is the most valuable agent for inhibition of preterm labor. Terbutaline 62-73 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 38-44 6130662-6 1983 Prenalterol, a selective beta 1-agonist, did not stimulate cAMP accumulation, while terbutaline, a selective beta 2-agonist, exerted a potent stimulation. Terbutaline 84-95 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 109-115 6132819-5 1983 The haemodynamic effects of the terbutaline infusion can be explained by a reflex response to the vasodilatation induced by stimulation of the vascular beta 2-receptors, while the effects of prenalterol can mainly be accounted for by a direct action on beta 1-receptors in the heart. Terbutaline 32-43 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 152-158 7282714-4 1981 On a molar basis among beta 2 agonists, terbutaline sulfate was considerably more stable than epinephrine hydrochloride or isoproterenol hydrochloride. Terbutaline 40-59 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 23-29 6128186-5 1982 Following study drug there was a 100 percent inhibition of the beta 1 terbutaline effect, and an approximate 83 percent inhibition of the beta 2 terbutaline effect. Terbutaline 145-156 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 138-144 7136993-1 1982 To assess the response of the right and left ventricles to the subcutaneous administration of terbutaline sulfate, a beta-2 selective agonist, we evaluated 14 patients with chronic obstructive pulmonary disease (COPD) with equilibrium radionuclide angiography (RNA). Terbutaline 94-113 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 117-123 6123517-0 1982 A time-saving method for the determination of the beta 2 sympathomimetics terbutaline, salbutamol and fenoterol. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 50-56 7096576-1 1982 Terbutaline is a selective beta 2 agonist used predominantly in the treatment of asthma. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 27-33 6958476-3 1982 Group 1 was treated with corticosteroids and group 2 with corticosteroids and the beta 2-adrenergic agonist terbutaline. Terbutaline 108-119 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-88 6273481-0 1981 [Beta 1-, beta 2-effects of ritrodine and terbutaline in the treatment of preterm labor (author"s transl)]. Terbutaline 42-53 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 10-16 6273481-3 1981 beta 2-effects of terbutaline and ritodrine in the treatment of preterm labor. Terbutaline 18-29 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-6 6138298-4 1983 The increase in SCC observed after terbutaline (beta 2-agonist) was similar to the increase after isoproterenol (beta 1- and beta 2-agonist). Terbutaline 35-46 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 434583-2 1979 Simultaneous ingestion of terbutaline and Tedral resulted in significantly greater bronchodilation than after either agent alone, which supports the concomitant use of beta-2 agonists and theophylline agents when treating patients with airflow obstruction. Terbutaline 26-37 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 168-174 7226928-1 1981 To assess the response of the left ventricle to subcutaneously administered terbutaline sulfate, a proposed beta-2 selective agonist, we evaluated 12 patients who had suffered previous myocardial infarctions using equilibrium radionuclide angiography. Terbutaline 76-95 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 108-114 6255217-2 1980 Maximum urethral closure pressure was recorded before and after the administration of terbutaline, a beta-2 agonist. Terbutaline 86-97 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 101-107 6258957-10 1980 "Selective" beta2-stimulants such as terbutaline or salbutamol induced no relaxation. Terbutaline 37-48 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 12-17 682845-0 1978 [Broncho-relaxing activity of Terbutaline, an aerosol of beta 2 sympathomimetic agent. Terbutaline 30-41 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 57-63 31829-3 1978 In this study the beta2 selectivity of SM 220 was poorer than that of terbutaline. Terbutaline 70-81 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 18-23 25467-1 1978 The development of beta2-specific sympathomimetic bronchodilators (rimiterol, salbutamol, terbutaline) has made the basic treatment of asthmatic patients more safe and effective. Terbutaline 90-101 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 19-24 34874-3 1978 The beta-2-adrenergic drugs, salbutamol and terbutaline, had an eosinopenic effect. Terbutaline 44-55 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 26113-9 1978 It is concluded that there is a small, clinically insignificant, difference in the onset of action of isoprenaline compared with that of the selective beta2-stimulating aerosol, terbutaline. Terbutaline 178-189 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 151-156 1198087-2 1975 During the run-in period, as well as during the practolol period, a long-acting beta2-stimulator, terbutaline, was given in the dose of 5 mg three times daily. Terbutaline 98-109 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 80-85 20550-3 1977 The beta2-adrenergic agonists salbutamol, terbutalin, and fenoterol were considerably less effective than the naturally occurring catecholamines. Terbutaline 42-52 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-9 192771-2 1977 We applied a strong beta-2 stimulus (terbutaline, 5.0 mg orally) at weekly intervals for up to three weeks in 19 stable asthmatics and bronchitics while commencing 5.0 mg terbutaline three times daily. Terbutaline 37-48 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 20-26 319711-3 1977 However, only the newer, selective beta-2 agonists, metaproterenol and terbutaline, produced significantly prolonged action upon small as well as large airways and lung volumes. Terbutaline 71-82 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 35-41 1031587-0 1976 [Functional study of the bronchodilator effect of a new beta-2-stimulant (terbutaline) administered subcutaneously]. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 56-62 1221951-0 1975 [Study of the ventilatory and cardiocirculatory effects of a new adrenergic beta-2-stimulant (terbutaline) in subjects affected by obstructive bronchial disease]. Terbutaline 94-105 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 76-82